PreveCeutical Announces First Cannabis Product for Treatment of Anxiety

- August 8th, 2018

PreveCeutical Medical Inc. (CSE:PREV, OTCQB:PRVCF, FSE:18H) (the “Company” or “PreveCeutical”), announces the first product development program of the Company’s newly created medicinal cannabis division is focusing on the development of cannabinoids as a preventive treatment for anxiety disorders using PreveCeutical’s nasal delivery, sustained release, Sol-gel (“Sol-gel”) delivery platform.

PreveCeutical Medical Inc. (CSE:PREV, OTCQB:PRVCF, FSE:18H) (the “Company” or “PreveCeutical”), announces the first product development program of the Company’s newly created medicinal cannabis division is focusing on the development of cannabinoids as a preventive treatment for anxiety disorders using PreveCeutical’s nasal delivery, sustained release, Sol-gel (“Sol-gel”) delivery platform. For further information on the Company’s new medicinal cannabis division, see news release dated July 24, 2018.

The goal of the medicinal cannabis division’s product development program is to create an effective therapy for anxiety that can be administered subtly and infrequently, addressing concerns of currently available treatments for anxiety disorders.

Anxiety disorders refer to a group of mental disorders characterized by feelings of anxiety and fear, including generalised anxiety disorder, panic disorder, social anxiety disorder, obsessive-compulsive disorder and post-traumatic stress disorder. Symptoms range from mild to severe, however, the duration of symptoms typically experienced by those with anxiety disorders can make it a chronic disorder rather than an episodic disorder. The Anxiety Disorders Association of Canada claims that one in four Canadians will suffer from an anxiety disorder in their lifetime.

According to the Mayo Clinic, a common approach to treating anxiety is to prescribe selective serotonin reuptake inhibitors (“SSRIs”). However, common treatments are not always effective, and are known to have side effects, including insomnia, agitation and sexual dysfunction. Patients that do not respond to SSRIs or experience negative side effects may now look to cannabinoids as an alternative therapy.

Anxiety disorders can also be associated with social stigma, which can make obvious or frequent administration of medications undesirable for patients. PreveCeutical’s Sol-gel product development program aims to create an effective, subtly administered cannabidiol in a sustained, low dose, enabling it to be administered as infrequently as once every few days.

About PreveCeutical

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.

PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for type 2 diabetes and obesity; a Sol-gel drug delivery program; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9® is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. This product is available on the Company’s website.

For more information about PreveCeutical, please visit www.PreveCeutical.com, follow us on Twitter: http://twitter.com/PreveCeuticals and Facebook: www.facebook.com/PreveCeutical.

On Behalf of the Board of Directors

“Stephen Van Deventer”
Chairman, CEO and President

For further information, please contact:

Deanna Kress
Director of Corporate Communications & Investor Relations
+1-778-999-6063
deanna@PreveCeutical.com

Forward-Looking Statements:

This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations and orientations regarding the future including, without limitation, the ability of the Company to develop and bring its cannabis-based products to market, the efficacy of the Company’s products, matters related to the Company’s current and planned research and development programs, including the use of the Sol-gel program for treatment of anxiety disorders using cannabinoids, the Company’s anticipated business plans and its prospect of success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as “plans”, “expects”, “may”, “intends”, “anticipates”, “believes”, “proposes” or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward looking statements are based on certain assumptions regarding the Company, including expected growth, results of operations, performance, industry trends and growth opportunities. Actual results could also differ from those projected in any forward-looking statements due to numerous factors including, risks and uncertainties relating to the inability of the Company, to, among other things, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities, commercialise therapeutic and diagnostic technologies, execute its proposed business plans, pursue business partnerships, complete its research and product development programs as planned and obtain the financing required to carry out its planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the healthcare and cannabis industries in Canada may also adversely affect the future results or performance of the Company. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although the Company believes that the statements, beliefs, plans, expectations, intentions and assumptions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations intentions or assumptions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-to-time. These reports and the Company’s filings are available at www.sedar.com.

Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.

Click here to connect with PreveCeutical Medical Inc. (CSE:PREV, OTCQB:PRVCF, FSE:18H) for an Investor Presentation. 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select All
Select None

By selecting company or companies above, you are giving consent to receive email from those companies. And remember you can unsubscribe at any time

Tags

2 responses to “PreveCeutical Announces First Cannabis Product for Treatment of Anxiety

Leave a Reply

Your email address will not be published. Required fields are marked *